News AbbVie's Cerevel takeover delivers Parkinson's approval The first drug from AbbVie's $8.7 billion takeover of Cerevel two years ago, Parkinson's disease therapy Juvmo, has won FDA approval.
News Iambic files IPO after signing up AbbVie as new partner In the space of a day, Iambic has filed an IPO, released the latest version of its AI platform, and signed a multi-year alliance with AbbVie.
News AbbVie charts a new course for CGRPs in menstrual migraine AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine.
News AbbVie's cancer TCE etentamig hits the mark in myeloma AbbVie has reported positive results with CD3xBCMA bispecific etentamig in multiple myeloma, but can it break into a crowded market?
News Another 340B lawsuit gets underway, in Illinois Three pharma groups have opened a new front in their legal challenge to the federal 340B drug pricing programme in the US.
News EU first to clear AbbVie's Rinvoq for alopecia areata AbbVie's fast-growing JAK inhibitor Rinvoq has been cleared for alopecia areata in the EU, its first market for the hair loss disorder.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.